Pharma Mar S.A./€PHM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
- Ticker
- €PHM
- Sector
- Health
- Primary listing
- BME
- Employees
- 505
- Headquarters
- Madrid, Spain
- Website
- www.pharmamar.com
Pharma Mar S.A. Metrics
BasicAdvanced
€1.1B
16.50
€3.94
0.47
€1.00
1.54%
Price and volume
Market cap
€1.1B
Beta
0.47
52-week high
€106.00
52-week low
€65.00
Average daily volume
35K
Dividend rate
€1.00
Financial strength
Current ratio
2.357
Quick ratio
1.834
Long term debt to equity
0.153
Total debt to equity
0.296
Dividend payout ratio (TTM)
25.35%
Interest coverage (TTM)
69.72%
Profitability
EBITDA (TTM)
56.553
Gross margin (TTM)
93.33%
Net profit margin (TTM)
28.80%
Operating margin (TTM)
21.26%
Effective tax rate (TTM)
-28.93%
Revenue per employee (TTM)
€470,000
Management effectiveness
Return on assets (TTM)
8.41%
Return on equity (TTM)
31.47%
Valuation
Price to earnings (TTM)
16.501
Price to revenue (TTM)
4.752
Price to book
4.78
Price to tangible book (TTM)
4.87
Price to free cash flow (TTM)
27.188
Free cash flow yield (TTM)
3.68%
Free cash flow per share (TTM)
2.394
Dividend yield (TTM)
1.54%
Growth
Revenue change (TTM)
32.42%
3-year revenue growth (CAGR)
12.11%
10-year revenue growth (CAGR)
2.42%
What the Analysts think about Pharma Mar S.A.
Analyst ratings (Buy, Hold, Sell) for Pharma Mar S.A. stock.
Analyst projections of the future price of Pharma Mar S.A. stock.
Bulls say / Bears say
Recurring revenue rose 30% to €137.4 million in the first nine months of 2026, with US Zepzelca royalties up 56% and commercial sales growing in Germany, Austria and Switzerland. This gives PharmaMar a stronger base of repeat income than one-off licence payments alone. (El Español, 1stOncology)
Zepzelca has gained first-line maintenance approval in the EU and the UK, backed by trial results showing a 27% lower risk of death versus atezolizumab alone. Wider authorised use could create room for further sales growth as new markets launch. (Immedica Pharma, AllSci)
PharmaMar ended September with €109.8 million of net cash, giving it financial room to fund research and commercial expansion without relying immediately on new equity. (1stOncology)
The FDA withdrew Zepzelca’s second-line small-cell lung cancer indication after the Phase 3 LAGOON trial failed to show a survival benefit. That removes one use for the company’s lead drug and highlights the risk of relying on its clinical results. (CURE Today, Fierce Pharma)
Net profit fell 43% and EBITDA fell 42% in the first nine months, even as revenue grew 12%. The comparison was weighed down by prior-year licence income and grants, but the sharp swings show how reported earnings can depend on non-recurring items. (Forbes España)
European approval does not guarantee quick commercial uptake: reimbursement is decided country by country, and Germany, Austria and Switzerland together generated €14.9 million in sales through September. Slow access decisions could delay the payoff from the European launch. (StockAnalysis, 1stOncology)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Pharma Mar S.A. Financial Performance
Revenues and expenses
Pharma Mar S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Pharma Mar S.A.
AllEURUSDGBP
Fund name | Fund size | €PHM weighting |
|---|---|---|
Xtrackers Spain€XESD | €282M | 0.10% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.10% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.10% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.10% |
iShares Ageing Population$AGED | $953M | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.